Paragon (FNA) | Financial Analysis & Statements
Paragon 28 Inc. Small-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2024Income Metrics
Revenue
71.7M
Gross Profit
52.3M
72.92%
Operating Income
-6.4M
-8.97%
Net Income
-11.1M
-15.50%
Balance Sheet Metrics
Total Assets
290.7M
Total Liabilities
160.1M
Shareholders Equity
130.6M
Debt to Equity
1.23
Cash Flow Metrics
Operating Cash Flow
-7.0M
Free Cash Flow
-6.2M
Revenue & Profitability Trend
Quarter Income Flow
Dec 31, 2024
Annual Income Flow
2024
Paragon Income Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 256.2M | 216.4M | 181.4M | 147.5M | 111.0M |
| Cost of Goods Sold | 64.7M | 52.0M | 32.1M | 28.0M | 25.1M |
| Gross Profit | 191.5M | 164.4M | 149.3M | 119.4M | 85.9M |
| Gross Margin % | 74.7% | 76.0% | 82.3% | 81.0% | 77.4% |
| Operating Expenses | |||||
| Research & Development | 27.1M | 30.1M | 24.6M | 16.1M | 11.2M |
| Selling, General & Administrative | 205.2M | 180.0M | 159.3M | 114.1M | 72.6M |
| Other Operating Expenses | - | - | - | - | - |
| Total Operating Expenses | 232.3M | 210.1M | 184.0M | 130.2M | 83.8M |
| Operating Income | -40.8M | -45.7M | -34.7M | -10.8M | 2.1M |
| Operating Margin % | -15.9% | -21.1% | -19.1% | -7.3% | 1.9% |
| Non-Operating Items | |||||
| Interest Income | - | - | - | - | - |
| Interest Expense | 11.5M | 5.2M | 4.1M | 1.7M | 602.0K |
| Other Non-Operating Income | -1.2M | -6.5M | -26.9M | -486.0K | 3.6M |
| Pre-tax Income | -53.5M | -57.3M | -65.7M | -13.0M | 5.0M |
| Income Tax | 1.2M | 213.0K | -64.0K | 713.0K | 1.5M |
| Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% | 30.4% |
| Net Income | -54.6M | -57.5M | -65.6M | -13.7M | 3.5M |
| Net Margin % | -21.3% | -26.6% | -36.2% | -9.3% | 3.2% |
| Key Metrics | |||||
| EBITDA | -23.4M | -31.3M | -20.9M | -2.3M | 12.0M |
| EPS (Basic) | - | $-0.70 | $-0.87 | $-0.18 | $0.04 |
| EPS (Diluted) | - | $-0.70 | $-0.87 | $-0.18 | $0.04 |
| Basic Shares Outstanding | - | 82087329 | 77770588 | 76447287 | 67307195 |
| Diluted Shares Outstanding | - | 82087329 | 77770588 | 76447287 | 67307195 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Paragon Balance Sheet From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 34.6M | 75.6M | 38.5M | 109.4M | 17.5M |
| Short-term Investments | - | - | - | - | - |
| Accounts Receivable | 39.0M | 37.3M | 37.7M | 25.9M | 20.0M |
| Inventory | 90.0M | 90.0M | 61.3M | 40.2M | 32.2M |
| Other Current Assets | 4.0M | 4.0M | 4.7M | 3.1M | 617.0K |
| Total Current Assets | 168.8M | 207.8M | 142.7M | 179.5M | 71.8M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 73.8M | 62.9M | 45.7M | 38.8M | 27.7M |
| Goodwill | 71.3M | 72.6M | 73.3M | 29.2M | 3.3M |
| Intangible Assets | 20.4M | 21.7M | 22.4M | 16.5M | 3.3M |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 4.7M | 3.6M | 3.3M | 0 | 100.0K |
| Total Non-Current Assets | 121.9M | 124.9M | 113.1M | 55.0M | 25.8M |
| Total Assets | 290.7M | 332.7M | 255.8M | 234.5M | 97.6M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 16.0M | 21.7M | 14.9M | 13.0M | 8.8M |
| Short-term Debt | 640.0K | 640.0K | 728.0K | 153.0K | 2.2M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 1.4M | 883.0K | 3.8M | 1.9M | 469.0K |
| Total Current Liabilities | 48.1M | 51.2M | 68.5M | 34.0M | 22.1M |
| Non-Current Liabilities | |||||
| Long-term Debt | 110.0M | 109.8M | 42.2M | 7.5M | 4.0M |
| Deferred Tax Liabilities | 18.0K | 233.0K | 342.0K | 78.0K | 0 |
| Other Non-Current Liabilities | 1.3M | 1.0M | 1.6M | 840.0K | - |
| Total Non-Current Liabilities | 112.0M | 111.7M | 44.7M | 8.4M | 4.0M |
| Total Liabilities | 160.1M | 163.0M | 113.2M | 42.4M | 26.1M |
| Equity | |||||
| Common Stock | 837.0K | 827.0K | 776.0K | 763.0K | 467.0K |
| Retained Earnings | -178.3M | -123.6M | -66.1M | -463.0K | 12.4M |
| Treasury Stock | 6.0M | 6.0M | 6.0M | 6.0M | 5.4M |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 130.6M | 169.7M | 142.6M | 192.2M | 71.5M |
| Key Metrics | |||||
| Total Debt | 110.7M | 110.4M | 42.9M | 7.6M | 6.3M |
| Working Capital | 120.7M | 156.6M | 74.2M | 145.6M | 49.7M |
Balance Sheet Composition
Paragon Cash Flow Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -54.6M | -57.5M | -65.6M | -13.7M | 3.5M |
| Depreciation & Amortization | 18.5M | 15.5M | 13.7M | 9.0M | 6.4M |
| Stock-Based Compensation | 13.0M | 12.4M | 10.4M | 4.9M | 1.8M |
| Working Capital Changes | -19.8M | -26.8M | -34.9M | -18.4M | -20.0M |
| Operating Cash Flow | -41.6M | -55.4M | -76.2M | -17.0M | -6.7M |
| Investing Activities | |||||
| Capital Expenditures | -14.5M | -25.7M | -40.2M | -17.5M | -9.1M |
| Acquisitions | 0 | 0 | -18.5M | -15.0M | 0 |
| Investment Purchases | - | - | - | - | - |
| Investment Sales | - | - | - | - | - |
| Investing Cash Flow | -14.5M | -25.7M | -58.7M | -32.5M | -9.1M |
| Financing Activities | |||||
| Share Repurchases | - | 0 | 0 | -561.0K | -1.5M |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | 0 | 100.0M | 36.0M | 10.0M | 458.0K |
| Debt Repayment | -640.0K | -30.7M | -570.0K | -6.0M | -14.5M |
| Financing Cash Flow | -3.5M | 125.3M | 33.7M | 130.7M | 12.4M |
| Free Cash Flow | -44.1M | -91.9M | -92.3M | -24.6M | -9.7M |
| Net Change in Cash | -59.6M | 44.2M | -101.3M | 81.2M | -3.5M |
Cash Flow Trend
Paragon Key Financial Ratios
Valuation Ratios
Forward P/E
-27.85
Price to Book
8.41
Price to Sales
4.29
PEG Ratio
-27.85
Profitability Ratios
Profit Margin
-21.33%
Operating Margin
-8.97%
Return on Equity
-36.39%
Return on Assets
-8.18%
Financial Health
Current Ratio
3.51
Debt to Equity
86.22
Beta
1.47
Per Share Data
EPS (TTM)
$-0.66
Book Value per Share
$1.56
Revenue per Share
$3.08
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| FNA | 1.1B | - | 8.41 | -36.39% | -21.33% | 86.22 |
| Abbott Laboratories | 160.7B | 25.97 | 3.09 | 12.36% | 13.90% | 26.79 |
| Boston Scientific | 97.6B | 27.49 | 4.02 | 11.84% | 17.29% | 48.92 |
| Novocure | 1.5B | -10.32 | 4.04 | -38.89% | -20.79% | 72.95 |
| UFP Technologies | 1.5B | 22.64 | 3.60 | 17.82% | 11.33% | 36.45 |
| Alphatec Holdings | 1.5B | -10.64 | 126.27 | -630.66% | -18.76% | 1,654.48 |
Financial data is updated regularly. All figures are in the company's reporting currency.
